1. History
- Onset and timing: When did the flare begin? Acute vs. gradual worsening? Seasonal pattern (winter exacerbation is common)? [1-2]
- Symptom characterization: Pruritus severity, pain, burning, skin tightness, cracking/bleeding of plaques
- Triggers: Recent infection (especially streptococcal pharyngitis), psychological stress, new medications (lithium, beta-blockers, antimalarials, NSAIDs, rapid corticosteroid taper), sunburn, alcohol binge, trauma (Koebner phenomenon) [1][3]
- Progression: Localized worsening vs. new widespread lesions; prior BSA involvement vs. current
- Treatment history: Current topical/systemic regimen, recent medication changes, adherence, prior biologic use and response
- Associated symptoms: Joint pain/stiffness (psoriatic arthritis screening), nail changes, fever, malaise [1]
- Important negatives: No pustules, no widespread erythema (>75% BSA), no systemic symptoms (fever, chills, hemodynamic instability)
2. Alarm Features
- Erythrodermic psoriasis (>75% BSA involvement): hypothermia or hyperthermia, tachycardia, dehydration, high-output cardiac failure, electrolyte disturbances — this is a dermatologic emergency [4-5]
- Generalized pustular psoriasis (GPP): widespread sterile pustules, fever, leukocytosis; mortality 4–7%, with sepsis as the primary cause of death; ~17% develop severe systemic complications (renal failure, cardiac failure) [6]
- Signs of secondary infection: purulence, expanding cellulitis, fever, sepsis
- Rapid onset after abrupt corticosteroid withdrawal (topical or systemic) [1][5]
- New joint swelling, dactylitis, or enthesitis suggesting psoriatic arthritis flare
- Features suggesting alternative dangerous diagnosis: palmar/sole papules (secondary syphilis), atypical lymphocytes (cutaneous T-cell lymphoma) [3]
3. Medications
Common triggers/exacerbators
- Lithium, beta-blockers, antimalarials (chloroquine/hydroxychloroquine), NSAIDs, ACE inhibitors, rapid taper of systemic or potent topical corticosteroids [1][5]
- Immune checkpoint inhibitors can induce psoriasiform eruptions [7]
Treatments — Mild flare (<5% BSA)
- Topical corticosteroids (first-line): high-potency (clobetasol 0.05%, fluocinonide 0.05%) for trunk/extremities; low-potency for face/intertriginous areas [4-5]
- Vitamin D analogues (calcipotriene): combine with topical steroids for superior efficacy [4-5]
- Calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus): preferred for face and flexural areas [4]
- Keratolytics (salicylic acid 2–6%): for thick plaques before applying other topicals [5]
Treatments — Moderate-to-severe flare (>5% BSA)
- Phototherapy: narrowband UVB [4-5]
- Systemic nonbiologics: methotrexate, cyclosporine (rapid onset, good for acute flares), acitretin, apremilast [8-9]
- Biologics: IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), IL-23 inhibitors (guselkumab, risankizumab), TNF-α inhibitors (infliximab for rapid onset) [4][10]
Contraindicated/caution
- Avoid initiating or rapidly tapering systemic corticosteroids — risk of rebound flare, erythroderma, or GPP [1][5]
- High-potency topical steroids: limit to ≤4 weeks on body; taper over 2 weeks to avoid rebound [5]
4. Diet
- Alcohol avoidance: Alcohol consumption is a known trigger and worsens disease severity [1][11]
- Mediterranean diet: anti-inflammatory pattern with fruits, vegetables, olive oil, fish (omega-3 rich), legumes, and nuts — associated with improved psoriasis outcomes (NPF recommendation, strength 2B) [12]
- Omega-3 fatty acids: fish oil supplementation or dietary fish ≥3 times/week may reduce inflammation [12-13]
- Gluten-free diet: beneficial only in patients with confirmed celiac disease or positive antigliadin antibodies [12]
- Calorie restriction: recommended for overweight/obese patients; weight loss improves disease severity and treatment response [14-15]
- Avoid: excessive salt, high-sugar foods, processed/pro-inflammatory foods [13]
- Hydration: particularly important in erythrodermic flares due to transepidermal water loss
5. Review of Systems
- Musculoskeletal: Joint pain, morning stiffness >30 min, swollen digits (dactylitis), heel pain (enthesitis) — screen for psoriatic arthritis (affects ~1/3 of patients) [1][12]
- Psychiatric: Depression, anxiety, sleep disturbance, suicidal ideation (psoriasis significantly impacts quality of life) [4]
- Cardiovascular: Screen for metabolic syndrome components — hypertension, dyslipidemia, diabetes, obesity [1][5]
- Ophthalmologic: Uveitis (associated with psoriatic arthritis)
- GI: Symptoms of inflammatory bowel disease (Crohn's, UC — associated comorbidity)
- Constitutional: Fever, chills, weight loss (concerning for erythrodermic/pustular variants or infection)
6. Collateral History and Family History
- Family history of psoriasis: Present in ~40% of patients; HLA-C06:02 is the strongest genetic risk allele [1]
- Family history of autoimmune disease: Celiac disease, inflammatory bowel disease, rheumatoid arthritis
- Social context: Psychosocial stressors (major life events, work stress), substance use (alcohol, tobacco), occupational exposures
- Collateral from dermatologist/PCP: Prior PASI scores, treatment history, biologic failures, biopsy results
7. Risk Factors
- Genetic: Family history, HLA-C06:02 positivity [1]
- Infections: Streptococcal pharyngitis (especially guttate flares), HIV [1][5]
- Obesity: Both a risk factor and trigger; adipose tissue produces pro-inflammatory adipokines [1][15]
- Smoking: Increases free radical production and inflammation; dose-dependent worsening [1][15]
- Alcohol: Increases TNF-α expression and disease severity [11][15]
- Stress: Psychological stress is one of the most commonly reported triggers [1][3]
- Medications: Lithium, beta-blockers, antimalarials, rapid steroid withdrawal [1]
- Seasonal: Cold weather, low humidity, reduced UV exposure (winter exacerbation) [2][5]
- Trauma: Koebner phenomenon — new lesions at sites of skin injury
8. Differential Diagnosis
- Atopic dermatitis: Flexural distribution, poorly demarcated, intensely pruritic, lacks silvery scale [1][4]
- Seborrheic dermatitis: Greasy, adherent scale on scalp/face/chest; overlaps with "sebopsoriasis" [1][16]
- Tinea corporis: Central clearing, positive KOH prep; most common misdiagnosis globally [1][5]
- Pityriasis rosea: Herald patch, collarette scale, follows skin cleavage lines, self-limited [1][5]
- Secondary syphilis: Psoriasiform papules on palms/soles (spared in guttate psoriasis); RPR/VDRL to rule out [1][5]
- Cutaneous T-cell lymphoma (mycosis fungoides/Sézary): Poorly demarcated patches, atypical lymphocytes on biopsy; consider flow cytometry in erythrodermic presentations [3][16]
- Pityriasis rubra pilaris: Erythroderma with "skip areas," palmoplantar keratoderma [3]
- Drug eruption / AGEP: Acute generalized exanthematous pustulosis mimics pustular psoriasis; onset <2 weeks after offending drug (penicillins, macrolides, quinolones) [5]
- Contact dermatitis, nummular eczema, lichen planus, subacute cutaneous lupus [1][17]
9. Past Medical History
- Prior psoriasis subtype, age of onset, frequency and severity of flares
- Previous treatments and responses (topicals, phototherapy, systemics, biologics)
- History of psoriatic arthritis or nail psoriasis
- Comorbidities: metabolic syndrome, cardiovascular disease, diabetes, obesity, depression, IBD, celiac disease [1][4]
- Prior skin biopsies and results
- Immunosuppression history (HIV status, transplant, biologics)
- Surgical history (tonsillectomy for recurrent guttate psoriasis) [1]
10. Physical Exam
Vital signs
Skin exam
- Distribution: Extensor surfaces (elbows, knees), scalp, sacrum, intergluteal cleft, nails, genitalia [1][4]
- Morphology: Well-demarcated, erythematous plaques with silvery-white scale (classic); violaceous or bluish in darker skin tones [5]
- Auspitz sign: Pinpoint bleeding upon scale removal
- BSA estimation: Handprint method (~1% BSA per palm); classify mild (<3–5%), moderate (5–10%), severe (>10%) [4][18]
- Nail exam: Pitting, onycholysis, oil-drop sign, subungual hyperkeratosis [4]
- Intertriginous areas: Smooth, erythematous, well-demarcated patches without scale (inverse psoriasis) [4]
- Pustules: Sterile pustules on erythematous base → consider GPP or AGEP [6][19]
- Koebner phenomenon: New lesions at sites of trauma
Joint exam
11. Lab Studies
Routine flare (mild-moderate plaque): Labs generally not required [1]
Severe/erythrodermic/pustular flare
- CBC: Leukocytosis, neutrophilia (GPP), anemia [6][19]
- CMP: Electrolytes (hypocalcemia triggers GPP), renal function, albumin (hypoalbuminemia from protein loss), liver function [6][20]
- CRP/ESR: Elevated in systemic inflammation [19]
- Blood cultures: If febrile or concern for sepsis [6]
- Pustule culture: To confirm sterility and rule out infection [6]
Screening labs for systemic therapy initiation
- CBC, CMP, hepatitis B/C serologies, HIV, TB (QuantiFERON), lipid panel
- Pregnancy test (before methotrexate, acitretin, tazarotene)
Consider
- Rapid strep test / ASO titer (guttate flare) [1]
- RPR/VDRL (if secondary syphilis in differential) [1]
- Flow cytometry / Sézary cell count (if erythrodermic, to rule out CTCL) [3]
- Antigliadin antibodies / tTG-IgA (if considering gluten-free diet) [12]
12. Imaging
- Not routinely indicated for isolated skin flares
- Joint imaging if psoriatic arthritis suspected: X-rays of affected joints (pencil-in-cup deformity, periostitis); ultrasound or MRI for enthesitis/dactylitis
- Chest X-ray: If initiating biologic therapy or concern for TB/infection
13. Special Tests
- PASI (Psoriasis Area and Severity Index): Gold standard for clinical trial severity assessment; combines erythema, induration, scaling, and BSA [18]
- BSA (Body Surface Area): Handprint method for rapid estimation [18]
- DLQI (Dermatology Life Quality Index): Patient-reported outcome; score >10 indicates significant quality-of-life impact [18]
- Skin biopsy: When diagnosis uncertain; shows epidermal acanthosis, parakeratosis, Munro microabscesses, dilated dermal capillaries; spongiform pustules of Kogoj in GPP [1][16][19]
- KOH prep: To rule out tinea [5]
- Genetic testing: IL36RN mutations in suspected recurrent GPP [6][19]
- Dermoscopy: Regularly distributed dotted vessels, white scales (helps distinguish from eczema)
14. ECG
- Not routinely indicated for psoriasis flare
- Consider ECG if:
- Erythrodermic psoriasis with concern for high-output cardiac failure (tachycardia, volume overload) [1][9]
- Initiating medications with cardiac effects (e.g., cyclosporine → hypertension monitoring)
- Screening for cardiovascular comorbidity in patients with metabolic syndrome [4]
15. Assessment
Severity stratification
- Mild: <3–5% BSA, limited plaques, responsive to topicals [4]
- Moderate: 5–10% BSA, or involvement of special areas (scalp, palms/soles, genitalia, nails) refractory to topicals [4]
- Severe: >10% BSA, or erythrodermic/pustular variants, or significant quality-of-life impairment (DLQI >10) [4]
Typical presentation: Well-demarcated erythematous plaques with silvery scale on extensor surfaces, scalp, and trunk; worsened by identifiable trigger [4-5]
Atypical presentations to recognize
- Inverse psoriasis (intertriginous, lacks scale, mimics fungal infection) [4]
- Guttate psoriasis (small confetti-like papules post-streptococcal infection) [4]
- Erythrodermic and pustular variants (systemic illness, hemodynamic instability) [4][6]
Complications
- Secondary bacterial infection of fissured/excoriated plaques [5]
- Psoriatic arthritis (screen at every visit) [1]
- Cardiovascular disease, metabolic syndrome, depression [4]
- Treatment-related complications (hepatotoxicity with methotrexate, nephrotoxicity with cyclosporine)
16. Treatment Plan
Initial stabilization (erythrodermic/GPP)
- IV fluid resuscitation, electrolyte correction, temperature regulation, wound care [5-6]
- Cyclosporine for rapid disease control in acute erythrodermic flare; acitretin is most prescribed for GPP [9][20]
- Dermatology consultation emergently
Mild flare (<5% BSA) — Outpatient
- High-potency topical corticosteroid (clobetasol 0.05% or betamethasone dipropionate) BID to affected areas for up to 4 weeks [4-5]
- Add calcipotriene (vitamin D analogue) — combination is superior to monotherapy [4-5]
- Emollients liberally to reduce pruritus and improve barrier function [5]
- Taper topical steroids over 2 weeks once lesions clear (every other day × 1 week → twice weekly → stop) to prevent rebound [5]
- Transition to proactive maintenance: topical agent twice weekly to previously affected areas [4]
Moderate-to-severe flare (>5% BSA) — Outpatient with dermatology referral:
- Narrowband UVB phototherapy (2–3 sessions/week) [4-5]
- Systemic therapy if BSA >5% or refractory to topicals: [5]
- Methotrexate 7.5–25 mg/week (assess for 25% PASI reduction at 4 weeks; switch if inadequate) [5]
- Cyclosporine 2.5–5 mg/kg/day (rapid onset; limit to 1–2 years due to nephrotoxicity) [8-9]
- Apremilast 30 mg BID (PDE4 inhibitor; no lab monitoring required) [4]
- Biologics (first-line per AAD-NPF for moderate-to-severe): IL-23 inhibitors (risankizumab, guselkumab), IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) [4][10]
Scalp psoriasis: Calcipotriene/betamethasone dipropionate gel or foam for 4–12 weeks [5]
Nail psoriasis (>2 nails): Systemic therapy preferred over topicals [5]
The following figure summarizes the overall treatment algorithm:
17. Disposition
Admit
- Erythrodermic psoriasis (type 2/acute onset): hemodynamic instability, electrolyte derangements, high-output cardiac failure risk [5][9]
- Generalized pustular psoriasis: ~9% require ICU; average hospitalization >10 days [6][20]
- Secondary sepsis or severe superinfection
- Inability to manage fluid/electrolyte losses outpatient
Observation
Discharge (majority of flares)
- Mild-to-moderate plaque flare with stable vitals, no systemic symptoms
- Adequate outpatient follow-up arranged (dermatology within 2–4 weeks)
- Able to apply topical treatments and access prescriptions
Specialist consultation triggers
- BSA >5% or refractory to topicals → Dermatology [5]
- Joint symptoms → Rheumatology
- Erythrodermic or pustular psoriasis → Emergent dermatology [5-6]
- Depression/suicidality → Psychiatry
18. Follow Up / Return Precautions
Follow-up timing
- Mild flare: PCP or dermatology in 2–4 weeks to assess treatment response [4]
- New systemic therapy: follow-up in 4 weeks to assess PASI response (switch if <25% improvement on methotrexate) [5]
- Biologic initiation: per drug-specific monitoring schedule
Return precautions — advise patients to seek immediate care for:
- Rapidly spreading redness involving most of the body (erythroderma)
- New pustules appearing on red skin
- Fever, chills, or feeling systemically unwell
- Signs of skin infection (increasing warmth, swelling, pus, red streaking)
- New joint swelling or inability to use hands/feet
- Worsening despite 2–4 weeks of prescribed treatment
Patient counseling
- Psoriasis is chronic; flares are expected but manageable with consistent treatment [4]
- Avoid known triggers: stress, alcohol, smoking, abrupt medication changes [1]
- Do not abruptly stop topical or systemic corticosteroids [1][5]
- Maintain skin hydration with daily emollients [5]
- Weight management and Mediterranean-style diet as adjunctive measures [12][14]
- Screen for depression and seek mental health support as needed [4]
Expected recovery
- Mild-moderate plaque flares typically improve within 2–4 weeks of consistent topical therapy [4]
- Guttate psoriasis often self-resolves in weeks to months, though ~40% progress to chronic plaque disease [1]
References
1. Psoriasis. — Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Lancet. 2021.
2. The Impacts of Seasonal Factors on Psoriasis. — Yang J, Li G, Yue L, Dang E, Qiao P. Experimental Dermatology. 2025.
3. Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 6. Guidelines of Care for the Treatment of Psoriasis and Psoriatic Arthritis: Case-Based Presentations and Evidence-Based Conclusions. — Menter A, Korman NJ, Elmets CA, et al. Journal of the American Academy of Dermatology. 2011.
4. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. — Armstrong AW, Read C. The Journal of the American Medical Association. 2020.
5. Psoriasis: Recognition and Management Strategies. — Garner KK, Hoy KDS, Carpenter AM. American Family Physician. 2023.
6. GPP: Recognizing and Treating a Dermatologic Emergency. — National Psoriasis Foundation (2025). 2025.
7. Management of Immune Checkpoint Inhibitor-Related Toxicities. — Updated 2025-10-23. National Comprehensive Cancer Network.
8. Joint American Academy of Dermatology-National Psoriasis Foundation Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologic Therapies. — Menter A, Gelfand JM, Connor C, et al. Journal of the American Academy of Dermatology. 2020.
9. Management of Erythrodermic Psoriasis With Systemic Therapies: A Systematic Review. — Mastorino L, Leo F, Frigatti G, et al. American Journal of Clinical Dermatology. 2025.
10. FDA Orange Book. — FDA Orange Book. 2026.
11. Impact of Alcohol Consumption, Smoking, and Diet on the Severity of Plaque Psoriasis: A Comprehensive Assessment Using Clinical Scales and Quality of Life Measures. — Michalski P, Palazzo-Michalska V, Michalska-Bańkowska A, Bańkowski M, Grabarek BO. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2023.
12. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. — Ford AR, Siegel M, Bagel J, et al. JAMA Dermatology. 2018.
13. Evidence-Based Dietary Recommendations for Patients With Psoriasis: A Systematic Review. — Wang Q, Wang J, Sun X, et al. Clinical Nutrition. 2025.
14. Nutrition and Psoriasis: The Latest Evidence and How to Approach Nutrition in Clinical Practice. — Leung A, Kranyak A, Marquez-Grap G, Bhutani T. American Journal of Clinical Dermatology. 2025.
15. Lifestyle Changes for Treating Psoriasis. — Ko SH, Chi CC, Yeh ML, et al. The Cochrane Database of Systematic Reviews. 2019.
16. Psoriasis. — Boehncke WH, Schön MP. Lancet. 2015.
17. Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks. — Gisondi P, Bellinato F, Girolomoni G. Journal of Clinical Medicine. 2020.
18. Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting. — Gkini MA, Chinchay L, Lindsay CA, et al. The Journal of Rheumatology. 2025.
19. International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council. — Choon SE, van de Kerkhof P, Gudjonsson JE, et al. JAMA Dermatology. 2024.
20. An Analysis of Psoriasis Hospitalisation in Thailand. — Chaiyabutr C, Silpa-Archa N, Wongpraprarut C, et al. Archives of Dermatological Research. 2023.